Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
The outsourced pharmaceutical manufacturing sector is booming in aggregate, but the benefits are not evenly distributed. The Pharma Letter published an analysis showing that scale
This is the data Lilly has been building toward since Foundayo launched on April 1. The obesity approval came first. The cardiovascular safety data (ACHIEVE-4,
GSK under Luke Miels is a different company. The new CEO told us in February that oncology may offer “the most tempting targets” and that
The ADC modality is on its strongest run in history. Enhertu in early breast cancer. Datroway in first-line TNBC. sac-TMT plus Keytruda cutting progression risk
The biotech IPO wave keeps rolling. Parabilis Medicines set terms for an IPO of up to $475 million, which would rank as the year’s second-largest
CNBC put the number on it: $106 billion. That is total biotech M&A in 2026 through early June across 201 deals, putting the year on
Lilly’s 12th deal adds yet another modality to the most diversified pipeline build in pharmaceutical history. The company signed a collaboration worth up to $1.9
The China licensing wave just hit a new peak. On a single day, Pfizer signed a $10.5 billion deal with Innovent Biologics for 12 early-stage
ASCO 2026 was the most consequential oncology meeting in years. The plenary sessions set three new treatment standards in a single afternoon—Revolution’s daraxonrasib in pancreatic
Saturday’s ASCO plenary delivered three datasets that will change how cancer is treated. Revolution Medicines confirmed everything the topline promised and added the missing piece:
